GIPR and type 2 diabetes mellitus: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor co-agonist, which the FDA approved in May 2022 for patients with type 2 diabetes mellitus (T2DM).